Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

@article{Tang2010ComparisonOT,
  title={Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20},
  author={Gong Tang and Steven Shak and Soonmyung Paik and Stewart J. Anderson and J. P. Costantino and Charles Edward Geyer and Eleftherios P Mamounas and Donald Lawrence Wickerham and Norman Wolmark},
  journal={Breast Cancer Research and Treatment},
  year={2010},
  volume={127},
  pages={133-142}
}
The Oncotype DX® Recurrence Score® (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer. Adjuvant! was developed using SEER registry data and results from the Early Breast Cancer Clinical Trialists’ overview analyses to estimate outcome and benefit from adjuvant hormonal therapy and chemotherapy. In this report we compare the prognostic and predictive utility of these two tools in node-negative, ER-positive breast cancer. RS and… CONTINUE READING
58 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Risk of distant recurrence using oncotype DX in postmenopausal primary breast

  • M Dowsett, J Cuzick, C Wales
  • CANCER
  • 2009

Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

  • M Dowsett, J Cuzick, C Wales
  • ABSTR
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…